Phase 3 Readout
AMGN: Phase 3 Topline: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel
June 24, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 24, 2026
- Company
- AMGEN INC (AMGN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel
- Company
- AMGEN INC (AMGN)
- Indication
- KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Other upcoming events for AMGN
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast
Phase 2 StartPhase 2 Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safe
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evalu
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effica
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pemb